APOLLOMICS（冠科美博）宣布启动C-MET抑制剂APL-101的II期全球多中心临床试验SPARTA 评估不分肿瘤类型的各种MET失调；聚焦MET 14号外显子跳跃突变的非小细胞肺癌及有MET扩增和融合的肿瘤，包括非小细胞肺癌，多形性胶质母细胞瘤及其他肿瘤 中国杭州市和美国福斯特市报道, May 21, 2020 (GLOBE NEWSWIRE) -- Apollomics,...

Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101 - Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with...